Satellos Bioscience (MSCL) Q4 2024 earnings summary

Executive summary

• Completed Phase 1a clinical trial enrollment and dosing for SAT-3247 in 72 healthy volunteers, demonstrating safety and intended pharmacokinetic profile.

• Initiated Phase 1b trial in up to 10 adults with Duchenne muscular dystrophy (DMD), with data expected in Q2 2025.

• Presented initial Phase 1a data at a major scientific conference, confirming SAT-3247 was safe and well-tolerated.

• Advanced SAT-3247 as a potential first-in-class oral therapy for DMD.

Financial highlights

• Cash and short-term investments totaled $69.9 million as of December 31, 2024, up from $39.6 million a year earlier, primarily due to a US$40 million equity offering.

• Net loss for the year ended December 31, 2024, was $28.1 million ($0.25 loss per share), compared to $15.9 million ($0.18 loss per share) in 2023.

• R&D expenses rose to $19.6 million in 2024 from $8.8 million in 2023, driven by increased clinical and preclinical activity.

• G&A expenses increased to $8.2 million in 2024 from $6.6 million in 2023, reflecting higher headcount and compensation.

• Recognized a non-cash impairment of $3.9 million to fully write down an impaired intangible asset.

Outlook and guidance

• Cash on hand is expected to provide operating runway through 2026 and support advancement of SAT-3247 through Phase 2 clinical study.

• Phase 1b data in DMD patients anticipated in Q2 2025.